Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case report
Abstract Background Immunocompromised individuals, such as those affected by and treated for hematological malignancies, face a higher risk of prolonged SARS-CoV-2 infection. Increased disease risk is further compounded by limited treatment options. Currently, approved antiviral monotherapies agains...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-06-01
|
| Series: | Journal of the Egyptian National Cancer Institute |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43046-025-00291-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849768536650547200 |
|---|---|
| author | Nadia Bouhamdani Dominique Bouhamdani Cynthia Léger Josiane Stadler Nancy Saulnier |
| author_facet | Nadia Bouhamdani Dominique Bouhamdani Cynthia Léger Josiane Stadler Nancy Saulnier |
| author_sort | Nadia Bouhamdani |
| collection | DOAJ |
| description | Abstract Background Immunocompromised individuals, such as those affected by and treated for hematological malignancies, face a higher risk of prolonged SARS-CoV-2 infection. Increased disease risk is further compounded by limited treatment options. Currently, approved antiviral monotherapies against COVID-19 include remdesivir (Veklury) and nirmatrelvir/ritonavir (Paxlovid) which have stringent recommended prescribing windows within 7 and 5 days of symptom onset, respectively. Furthermore, these two antiviral therapies are approved for treatment lengths of 3 (remdesivir) and 5 days (Paxlovid). Case presentation Herein, we describe the successful treatment of prolonged COVID-19 in a patient with a history of diffuse large B-cell lymphoma with an extended combination therapy; remdesivir and nirmatrelvir/ritonavir. The patient presented with symptomatic COVID-19 that was unsuccessfully treated with a 10-day course of remdesivir. After 2 months of symptomatic infection, the patient was treated with remdesivir in combination with nirmatrelvir/ritonavir for 10 days, which quickly resolved the cough and cleared viral load. Conclusion Our case highlights the efficacy of administrating a combination treatment of remdesivir and nirmatrelvir/ritonavir outside recommended guidelines for the treatment of persistent COVID-19 infection in an immunocompromised individual. High-quality studies evaluating the usefulness of this combinatory therapy as a longer-course treatment in patients with neoplasms is warranted. |
| format | Article |
| id | doaj-art-b245fdc26fe141eb941bc06d9df67b7f |
| institution | DOAJ |
| issn | 2589-0409 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Journal of the Egyptian National Cancer Institute |
| spelling | doaj-art-b245fdc26fe141eb941bc06d9df67b7f2025-08-20T03:03:45ZengSpringerOpenJournal of the Egyptian National Cancer Institute2589-04092025-06-013711510.1186/s43046-025-00291-1Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case reportNadia Bouhamdani0Dominique Bouhamdani1Cynthia Léger2Josiane Stadler3Nancy Saulnier4Vitalité Health NetworkVitalité Health NetworkUniversité de SherbrookeUniversité de SherbrookeVitalité Health NetworkAbstract Background Immunocompromised individuals, such as those affected by and treated for hematological malignancies, face a higher risk of prolonged SARS-CoV-2 infection. Increased disease risk is further compounded by limited treatment options. Currently, approved antiviral monotherapies against COVID-19 include remdesivir (Veklury) and nirmatrelvir/ritonavir (Paxlovid) which have stringent recommended prescribing windows within 7 and 5 days of symptom onset, respectively. Furthermore, these two antiviral therapies are approved for treatment lengths of 3 (remdesivir) and 5 days (Paxlovid). Case presentation Herein, we describe the successful treatment of prolonged COVID-19 in a patient with a history of diffuse large B-cell lymphoma with an extended combination therapy; remdesivir and nirmatrelvir/ritonavir. The patient presented with symptomatic COVID-19 that was unsuccessfully treated with a 10-day course of remdesivir. After 2 months of symptomatic infection, the patient was treated with remdesivir in combination with nirmatrelvir/ritonavir for 10 days, which quickly resolved the cough and cleared viral load. Conclusion Our case highlights the efficacy of administrating a combination treatment of remdesivir and nirmatrelvir/ritonavir outside recommended guidelines for the treatment of persistent COVID-19 infection in an immunocompromised individual. High-quality studies evaluating the usefulness of this combinatory therapy as a longer-course treatment in patients with neoplasms is warranted.https://doi.org/10.1186/s43046-025-00291-1COVID- 19SARS-CoV- 2Hematological malignanciesDiffuse large B-cell lymphomaRemdesivirVeklury |
| spellingShingle | Nadia Bouhamdani Dominique Bouhamdani Cynthia Léger Josiane Stadler Nancy Saulnier Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case report Journal of the Egyptian National Cancer Institute COVID- 19 SARS-CoV- 2 Hematological malignancies Diffuse large B-cell lymphoma Remdesivir Veklury |
| title | Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case report |
| title_full | Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case report |
| title_fullStr | Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case report |
| title_full_unstemmed | Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case report |
| title_short | Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case report |
| title_sort | successful treatment of prolonged covid 19 with remdesivir and nirmatrelvir ritonavir in a patient with a history of diffuse large b cell lymphoma a case report |
| topic | COVID- 19 SARS-CoV- 2 Hematological malignancies Diffuse large B-cell lymphoma Remdesivir Veklury |
| url | https://doi.org/10.1186/s43046-025-00291-1 |
| work_keys_str_mv | AT nadiabouhamdani successfultreatmentofprolongedcovid19withremdesivirandnirmatrelvirritonavirinapatientwithahistoryofdiffuselargebcelllymphomaacasereport AT dominiquebouhamdani successfultreatmentofprolongedcovid19withremdesivirandnirmatrelvirritonavirinapatientwithahistoryofdiffuselargebcelllymphomaacasereport AT cynthialeger successfultreatmentofprolongedcovid19withremdesivirandnirmatrelvirritonavirinapatientwithahistoryofdiffuselargebcelllymphomaacasereport AT josianestadler successfultreatmentofprolongedcovid19withremdesivirandnirmatrelvirritonavirinapatientwithahistoryofdiffuselargebcelllymphomaacasereport AT nancysaulnier successfultreatmentofprolongedcovid19withremdesivirandnirmatrelvirritonavirinapatientwithahistoryofdiffuselargebcelllymphomaacasereport |